Avenue Therapeutics, Inc. Stock News

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma

Is (ATXI) Outperforming Other Medical Stocks This Year?

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide

Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings

Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

The logic behind the breakout strategy for stock selection is to identify stocks are trading within a narrow band.

NEW YORK, May 11, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

Stocks Analysis by Zacks Investment Research covering: Celgene Corporation, Bristol-Myers Squibb Company, Corcept Therapeutics Incorporated, Avenue Therapeutics Inc. Read Zacks Investment Research's l

During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

The e-poster (816) titled “Intravenous Tramadol is Effective in Management of Postoperative Pain Following Abdominoplasty: A 3-arm Randomized Controlled Trial” presents data from the Phase 3 abdom

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.